Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Role of PlasmaJet in Patients Undergoing Groin Node Dissection for Vulval Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* To be included in this study, all women should undergo BGND during their treatment pathway for histologically confirmed vulval cancer.~* Participant is willing and able to provide informed consent.~* Aged 18 years or above.~* Participant willing to allow General Practitioner and other health care professionals, if appropriate, to be notified of participation in study.~Exclusion Criteria:~* Women with vulval cancer who do not undergo BGND.~* Women with any previous groin surgery~* Women with any previous radiotherapy to the pelvic area including the groins~* Patient choice~* Women who are pregnant, lactating or planning pregnancy during the course of the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Surgery without trial (PJ) device (Type: NO_INTERVENTION): All steps of surgery are conducted as per standard practice in accordance with the current practice at the time. In all cases a bilateral inguino-femoral groin node dissection was performed, with en-bloc removal of the superficial and deep inguinal nodes with conservation of the long saphenous vein.
- Surgery with trial (PJ) device (Type: ACTIVE_COMPARATOR): Use of the PJ was limited to the randomised side only. All steps of surgery are conducted as per standard practice in accordance with the current practice at the time. In all cases a bilateral inguino-femoral groin node dissection was performed, with en-bloc removal of the superficial and deep inguinal nodes with conservation of the long saphenous vein. Haemostasis was ensured with diathermy and ties and just prior to wound closure, the surgeon used the PlasmaJet on the indicated groin to seal the lymph vessels and channels at a setting of 40% by spraying the argon plasma over the entire exposed surgical field at a distance of 10 mm from the surface to the tip of the instrument.

Based on this trial design, predict the completion outcome and termination type (if applicable).